QM · rank #19 · 2026-07-20
SNT
GPW · PLN · $881M (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +47.09% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +55.1% |
| Profit margin Net profit margin, trailing 12 months. | +16.1% |
| Market cap (USD) Size filter: > $300M required (USD-equivalent). | $881M |
| Anchor (recent) Close on 2026-06-19 | $296.80 |
| Anchor (far) Close on 2025-06-20 | $201.78 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Synektik S.A. (SNT@GPW) is a Central European medical technology company that produces proprietary radiopharmaceuticals and distributes advanced diagnostic and therapeutic systems, including da Vinci surgical robots and the Edison platform.
Rationale
Strong momentum (0.4709) and high ROE (0.5507) are backed by solid organic growth in continuing operations (82.9 mln PLN H1 net profit) and strong revenue visibility from a 163 mln PLN backlog and 112 mln PLN in recent order intake.
Material risks
- 1Loss of sole-supplier or exclusive distribution rights for key high-end therapeutic systems like da Vinci, which would severely impact hardware distribution margins.
- 2Trailing quality metrics are temporarily distorted by the 261.3 mln PLN one-off gain from the Syn2bio spin-off, masking the true run-rate profitability of continuing operations.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.